POSTER: MM-1043 Efficacy of Elranatamab (ELRA) in Combination With Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael Tomasson; Eli Gabayan; Syed Abbas Ali; Gabriel Afram; Sona Ghorashi; Trish Creel; Luisa Paccagnella; Carolyn Lou; Ola Landgren

doi:10.1016/S2152-2650(25)01317-5

$POSTER: MM-1043 Efficacy of Elranatamab (ELRA) in Combination With Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)$

Abstract

Peer reviewed

POSTER: MM-1043 Efficacy of Elranatamab (ELRA) in Combination With Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)

Michael Tomasson, Eli Gabayan, Syed Abbas Ali, Gabriel Afram, Sona Ghorashi, Trish Creel, Luisa Paccagnella, Carolyn Lou and Ola Landgren

Clinical lymphoma, myeloma and leukemia, Vol.25(Suppl 1), pp.S305-S305

09/2025

DOI: 10.1016/S2152-2650(25)01317-5

View Online

Details

Title: Subtitle: POSTER: MM-1043 Efficacy of Elranatamab (ELRA) in Combination With Carfilzomib (CFZ) and Dexamethasone (DEX) in the Phase 1b MagnetisMM-20 Trial in Relapsed or Refractory Multiple Myeloma (RRMM)
Creators: Michael Tomasson - University of Iowa
Eli Gabayan - Beverly Hills Cancer Center
Syed Abbas Ali - Sidney Kimmel Comprehensive Cancer Center
Gabriel Afram - Pfizer
Sona Ghorashi - Pfizer
Trish Creel - Pfizer
Luisa Paccagnella - Pfizer
Carolyn Lou - Pfizer
Ola Landgren - Sylvester Comprehensive Cancer Center
Resource Type: Abstract
Publication Details: Clinical lymphoma, myeloma and leukemia, Vol.25(Suppl 1), pp.S305-S305
DOI: 10.1016/S2152-2650(25)01317-5
ISSN: 2152-2650
Publisher: Elsevier Inc
Language: English
Date published: 09/2025
Academic Unit: Hematology, Oncology, and Blood & Marrow Transplantation; Health, Sport, and Human Physiology ; Internal Medicine
Record Identifier: 9984949520602771

Metrics

5 Record Views